JPMorgan Chase & Co. Trims Position in Sionna Therapeutics, Inc. $SION

JPMorgan Chase & Co. decreased its stake in shares of Sionna Therapeutics, Inc. (NASDAQ:SION) by 10.9% in the third quarter, HoldingsChannel reports. The institutional investor owned 1,978,626 shares of the company’s stock after selling 242,562 shares during the period. JPMorgan Chase & Co.’s holdings in Sionna Therapeutics were worth $58,191,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in SION. Braidwell LP purchased a new position in shares of Sionna Therapeutics during the second quarter worth approximately $18,770,000. Viking Global Investors LP grew its stake in Sionna Therapeutics by 8.2% in the second quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock worth $55,436,000 after purchasing an additional 242,427 shares in the last quarter. Geode Capital Management LLC grew its stake in Sionna Therapeutics by 113.4% in the second quarter. Geode Capital Management LLC now owns 289,275 shares of the company’s stock worth $5,020,000 after purchasing an additional 153,712 shares in the last quarter. Soleus Capital Management L.P. increased its holdings in Sionna Therapeutics by 56.7% during the 2nd quarter. Soleus Capital Management L.P. now owns 376,000 shares of the company’s stock worth $6,524,000 after purchasing an additional 136,000 shares during the period. Finally, Woodline Partners LP bought a new stake in Sionna Therapeutics during the 1st quarter valued at $837,000.

Insider Activity at Sionna Therapeutics

In other Sionna Therapeutics news, Director Orbimed Advisors Llc sold 29,063 shares of the firm’s stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $44.58, for a total value of $1,295,628.54. Following the completion of the sale, the director directly owned 3,530,702 shares in the company, valued at $157,398,695.16. This trade represents a 0.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Tpg Gp A, Llc sold 250,000 shares of Sionna Therapeutics stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $40.00, for a total transaction of $10,000,000.00. Following the completion of the transaction, the insider directly owned 6,494,962 shares in the company, valued at $259,798,480. This represents a 3.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 382,368 shares of company stock valued at $15,898,607 over the last 90 days. Insiders own 3.90% of the company’s stock.

Sionna Therapeutics Stock Performance

SION stock opened at $38.03 on Thursday. Sionna Therapeutics, Inc. has a one year low of $7.26 and a one year high of $45.00. The firm has a market cap of $1.70 billion and a price-to-earnings ratio of -7.81. The firm has a 50-day simple moving average of $40.02 and a two-hundred day simple moving average of $34.79.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on SION. Citigroup began coverage on Sionna Therapeutics in a research note on Tuesday. They set an “outperform” rating on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Sionna Therapeutics in a research report on Monday, December 29th. Wall Street Zen upgraded shares of Sionna Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. Royal Bank Of Canada reiterated an “underperform” rating and set a $24.00 price objective on shares of Sionna Therapeutics in a research note on Monday, December 1st. Finally, BTIG Research reissued a “buy” rating and issued a $58.00 price objective on shares of Sionna Therapeutics in a research note on Wednesday, January 14th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $47.63.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.